Abstract
Methods In here, we immunized, by the intramuscular route, 6 RM with 10 PFU of ALVAC-SIV at weeks, 0 (V0), 4 (V2), and with both ALVAC SIV and the SIVgp120 envelope proteins, adjuvanted with ALUM at week 12 (V3) and 24 (V4) and analyzed the profile of gene expression at 24 hours after each vaccination. In parallel, we studied the phenotypical and functional changes in the NK cell subsets after vaccination by multi parametric flow cytometry.
Highlights
NK cells play a pivotal role in the innate immunity and patrol various tissues, including mucosal sites, the portal of entry of HIV
We recently reproduced in the SIV mac251- rhesus macaque (RM) model the limited protection reported in the RV144 HIV vaccine trial in humans (32% protection from HIV acquisition), using similar vaccines (ALVAC-SIV & gp120)
These finding paralleled our results observed by FACS analysis that demonstrated an increased frequency of NK22 cells at mucosal sites
Summary
RV144-like trial in macaques using ALVAC-SIV & gp120 induces innate immunity and increases the frequency of NK22 & NKG2A+ cells in mucosal tissues. NP Liyanage1*, P Pegu, S Gordon, M Cameron, K Foulds, M Doster, M Vaccari, R Koup, M Roederer, R Sékaly, G Franchini
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
